FY2026 Financial Results | Achieved Profitability with Sales of 1.09 billion yen

Overview of Business Performance

For the fiscal year ending April 2026, consolidated sales reached 1,086.6 million yen (57.0% increase YoY), driven by expanded sales in the U.S., Europe, and Japan. Notably, sales of absorbable local hemostatic agents in the U.S. increased by 98.2%, contributing to a profitability turnaround with operating profit of 133.5 million yen. The company actively advances R&D, accelerating new approvals and clinical trials. Overall, sales expansion and profit recovery were achieved mainly overseas.

Outlook and Impact on Shareholders

The earnings forecast for the fiscal year ending April 2027 projects sales of 1,342.2 million yen (23.3% increase) and operating profit of 165.2 million yen (23.7% increase). The company plans to continue expanding sales of hemostatic agents mainly in the U.S., with growth anticipated in Europe and Japan, while accelerating R&D efforts. Financial position will be strengthened through equity issuance and fundraising, aiming for business expansion and sustained profitability. The company will focus on shareholder returns and growth strategies to enhance investment value.